CNS disorder specialist Intra-Cellular Therapies (Nasdaq: ITCI) has announced positive top-line results from Study 502, evaluating its depression candidate lumateperone.
The drug is being tested as an adjunctive therapy to antidepressants for major depressive disorder (MDD).
The trial met the primary efficacy endpoint and a key secondary endpoint, paving the way for a regulatory submission to broaden the label, expected later this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze